Decoding
Cardiovascular
Biology
CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics
We are building the largest human cardiac tissue multiomics database through our large hospital and academic network
Our company and technology was spun out of the Han Lab, University of Cambridge
01/03
Cardiovascular Disease is the world’s leading cause of death.
01/03
Our poor understanding of the complex biology of cardiovascular diseases has limited clinical translation and deterred investment:
Cardio
Oncology
Pipeline Growth 2015-19:
0%
0%
US R&D Spend 2016‑21:
$0B
$0B
Building and navigating large multiomic maps of human disease biology
Through the application of state-of-the-art computational modelling CardiaTec navigates high dimensional human tissue multiomics data to unravel the complex mechanisms driving disease progression. Our platform powers the discovery and development of novel therapeutics for cardiovascular diseases.
Proteomics
Transcriptomics
Epigenomics
Genomics
Proprietary Data Strategy
01/02
Team
Namshik Han
CTO & Co-founder
Thelma Zablocki
COO & Co-founder
Raphael Peralta
CEO & Co-founder
Woochang Hwang
Principal ML Scientist
Meabh MacMahon
Principal Data Scientist
Sara Ahrabi
Principal Target Discovery Scientist
Agata Rumianek
Associate Principal Cardiovascular Scientist
Franck Duclos
Director of Cardiovascular Science
Niall Santamaria
Board member
Diana Röttger
Board Member
Todd Kimmel
Board Member
Joseph Lehár
SAB Member
Dr Ian Dunham
SAB Member
Victor Dillard
SAB Member
Prof. Wilson Tang
SAB Member
News
12 September 2024
CardiaTec’s story featured by TechCrunch
10 September 2024
CardiaTec raises $6.5M in Seed funding, led by San Francisco-based Montage Ventures
19 June 2024
CardiaTec honoured as the AI Startup of the Year at the East England StartUp Awards 2024
22 February 2023
The story of our Co-Founder & CTO Prof. Namshik Han covered in Owkin’s “Humanity” book about AI augmented health
Details
Decoding
Cardiovascular
Biology
CardiaTec is a TechBio company leveraging large scale multiomics data to discover novel cardiovascular therapeutics
We are building the largest human cardiac tissue multiomics database through our large hospital and academic network
Our company and technology was spun out of the Han Lab, University of Cambridge
01/03
Cardiovascular Disease is the world’s leading cause of death.
01/03
Our poor understanding of the complex biology of cardiovascular diseases has limited clinical translation and deterred investment:
Cardio
Oncology
Pipeline Growth 2015-19:
0%
0%
US R&D Spend 2016‑21:
$0B
$0B
Building and navigating large multiomic maps of human disease biology
Through the application of state-of-the-art computational modelling CardiaTec navigates high dimensional human tissue multiomics data to unravel the complex mechanisms driving disease progression. Our platform powers the discovery and development of novel therapeutics for cardiovascular diseases.
Proteomics
Transcriptomics
Epigenomics
Genomics
Proprietary Data Strategy
01/02
Team
Namshik Han
CTO & Co-founder
Thelma Zablocki
COO & Co-founder
Raphael Peralta
CEO & Co-founder
Woochang Hwang
Principal ML Scientist
Meabh MacMahon
Principal Data Scientist
Sara Ahrabi
Principal Target Discovery Scientist
Agata Rumianek
Associate Principal Cardiovascular Scientist
Franck Duclos
Director of Cardiovascular Science
Niall Santamaria
Board member
Diana Röttger
Board Member
Todd Kimmel
Board Member
Joseph Lehár
SAB Member
Dr Ian Dunham
SAB Member
Victor Dillard
SAB Member
Prof. Wilson Tang
SAB Member
News
12 September 2024
CardiaTec’s story featured by TechCrunch
10 September 2024
CardiaTec raises $6.5M in Seed funding, led by San Francisco-based Montage Ventures
19 June 2024
CardiaTec honoured as the AI Startup of the Year at the East England StartUp Awards 2024
22 February 2023
The story of our Co-Founder & CTO Prof. Namshik Han covered in Owkin’s “Humanity” book about AI augmented health
Details